CUSIP No. 185063 10 4
Page
15
of 20
This Amendment
No. 5 on Schedule 13D amends the statement on Schedule 13D, dated June 7, 2016, which relates to the Common Stock, par value $0.001 per share (the Common Stock) of Clearside Biomedical, Inc. (the
Issuer) which was previously amended on Schedule 13D/A, dated January 20 and April 17, 2017, March 21, 2018 and July 17, 2019 filed by:
Hatteras Venture Advisors III, LLC (HVA III)
Hatteras Venture Partners III, LP (HVP III)
Hatteras Venture Affiliates III, LP (HV Affiliates)
Hatteras Venture Advisors IV SBIC, LLC (HVA SBIC)
Hatteras Venture Partners IV SBIC, LP (HVP SBIC)
Hatteras Venture Advisors IV, LLC (HVA IV)
Hatteras Venture Partners IV, LP (HVP IV)
Hatteras NC Fund, LP (Hatteras Fund)
John C. Crumpler
Robert A.
Ingram
Kenneth B. Lee
Clay B. Thorp
Douglas Reed
(collectively, the Reporting Persons).
Except as expressly amended below, the Schedule 13D, dated June 7, 2016, remains in effect.
Item 5.
|
Interest in Securities of the Issuer.
|
|
(a)
|
Aggregate number and percentage beneficially owned:
|
HVA III 1,429,518 or 3.2%
HVP III 1,310,512 or 3.0%
HV Affiliates 119,006 or less than 1%
HVA SBIC 3,064,467 or 6.9%
HVP SBIC 3,064,467 or 6.9%
HVA IV 490,435 or 1.1%
HVP
IV 387,475 or less than 1%
Hatteras Fund 102,960 or less than 1%
John C. Crumpler 4,984,420 or 11.2%
Robert A. Ingram 4,984,420 or 11.2%
Kenneth B. Lee 4,984,420 or 11.2%
Clay B. Thorp 5,014,920 or 11.3%
Douglas Reed 4,984,420 or 11.2%
|
(b)
|
Number of shares as to which the person has:
|
|
(i)
|
Sole power to vote or to direct the vote
|
HVA III 0
HVP III
0
HV Affiliates 0
HVA SBIC 0
HVP SBIC
0